Injury reactive myelin/oligodendrocyte-derived axon growth inhibition in the adult mammalian central nervous system.
Myelin inhibition is considered a constitutive, static, repulsive barrier not reactive to a central nervous system (CNS) lesion. However, recent evidence underlines the existence of considerable add-on axon growth inhibition upon CNS injury. This postlesional, reactive myelin/oligodendrocyte-derived inhibition will require the development of novel screening approaches and therapeutic reagents to promote axonal regeneration.